Myelodysplastic-myeloproliferative diseases

MeSH D054437 - myelodysplastic-myeloproliferative diseases

Favorite

Competitive Landscape

Events Timeline

Commercial

Clinical Trials

Competitive landscape

See list view

D001855:Bone marrow diseases

17 Companies

1 Drug

Success rate

D054437:

Myelodysplastic-myeloproliferative diseases

19 Companies

1 Drug

Success rate

D015477:Myelomonocytic leukemia chronic

16 Companies

1 Drug

Success rate

D054429:Myelomonocytic leukemia juvenile

0 Companies

0 Drugs

Success rate

D054438:Leukemia myeloid chronic atypical bcr-abl negative

0 Companies

0 Drugs

Success rate

Events Timeline

Commercial

No Data

Clinical Trials

Historical Success Rate

Phase 1

79%

27/34

Phase 2

26%

12/47

Phase 3

14%

2/14

Approved: 2Overall Success rate: 3%

All Clinical Trials

Therapeutic Areas:

All

Classification:

All

Approval:

All

Status:

All

Phases:

All

Company name

Phase 1

Phase 2

Phase 3

Phase 4

Drug Name

Amneal Pharmaceuticals

Imatinib,

Imatinib mesylate

Hikma Pharmaceuticals

Imatinib,

Imatinib mesylate